Phase I trial of the multi-kinase inhibitor cabozantinib, a CYP3A4 substrate, plus CYP3A4 interacting antiretroviral therapy in people living HIV and cancer (AMC087)

By sjmartinez • August 1, 2023

Haigentz M, Lee JY, Chiao EY, Aboulafia DM, Ratner L, Ambinder RF, Baiocchi RA, Mitsuyasu RT, Wachsman W, Sparano JA, Rudek MA. Phase I trial of the multi-kinase inhibitor cabozantinib, a CYP3A4 substrate, plus CYP3A4 interacting antiretroviral therapy in people living HIV and cancer (AMC087). Clin Cancer Res. 2023 Jul 31:CCR-23-1142. doi: 10.1158/1078-0432.CCR-23-1142. Epub ahead of print. PMID: 37523145.

Tags: CARE Unit, Infectious Diseases, Publications

Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis

Landovitz RJ, Delany-Moretlwe S, Fogel JM, Eshleman SH, Marzinke MA, Piwowar-Manning E, Richardson P, Halvas EK, Mellors JW, Persaud D, Kofron R, McCauley M, Rose[...]

Arrhythmogenic effects of acute electronic cigarette compared to tobacco cigarette smoking in people living with HIV

Ruedisueli I, Shi K, Lopez S, Gornbein J, Middlekauff HR. Arrhythmogenic effects of acute electronic cigarette compared to tobacco cigarette smoking in people living with[...]

Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis

Fogel JM, Piwowar-Manning E, Moser A, Hill T, Ahmed S, Cummings V, Mostafa HH, Wang Z, Jennings A, Gallardo-Cartagena JA, Figueroa MI, St Clair M,[...]